Histogenics Corp (NASDAQ:HSGX) gapped down prior to trading on Wednesday . The stock had previously closed at $0.41, but opened at $0.44. Histogenics shares last traded at $0.42, with a volume of 2700682 shares changing hands.

Several equities research analysts have commented on the stock. Zacks Investment Research raised shares of Histogenics from a “sell” rating to a “hold” rating in a report on Tuesday. Brookline Cap M reaffirmed a “buy” rating on shares of Histogenics in a report on Wednesday, August 1st. HC Wainwright reaffirmed a “buy” rating and issued a $3.50 price target on shares of Histogenics in a report on Monday, August 13th. BTIG Research lowered shares of Histogenics from a “buy” rating to a “neutral” rating and set a $3.50 price target on the stock. in a report on Wednesday, September 5th. Finally, Needham & Company LLC upped their price target on shares of Histogenics to $5.00 and gave the company a “buy” rating in a report on Thursday, September 6th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $3.25.

The firm has a market cap of $13.91 million, a P/E ratio of -0.41 and a beta of 1.02.

Histogenics (NASDAQ:HSGX) last posted its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.05). Equities analysts forecast that Histogenics Corp will post -0.83 EPS for the current fiscal year.

A number of large investors have recently bought and sold shares of the business. Virtu Financial LLC purchased a new stake in shares of Histogenics during the 3rd quarter worth about $117,000. JPMorgan Chase & Co. purchased a new stake in shares of Histogenics during the 1st quarter worth about $320,000. DRW Securities LLC purchased a new stake in shares of Histogenics during the 2nd quarter worth about $242,000. BlackRock Inc. boosted its stake in shares of Histogenics by 72.0% during the 2nd quarter. BlackRock Inc. now owns 54,753 shares of the biotechnology company’s stock worth $137,000 after acquiring an additional 22,927 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its stake in shares of Histogenics by 6.1% during the 2nd quarter. Renaissance Technologies LLC now owns 384,329 shares of the biotechnology company’s stock worth $961,000 after acquiring an additional 22,133 shares in the last quarter. 45.68% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Histogenics (HSGX) Shares Gap Down to $0.44” was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this report on another publication, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this report can be read at https://www.dailypolitical.com/2018/11/14/histogenics-hsgx-shares-gap-down-to-0-44.html.

Histogenics Company Profile (NASDAQ:HSGX)

Histogenics Corporation, a clinical-stage company, focuses on the development of restorative cell therapies in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.

Further Reading: Earnings Reports

Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.